端粒酶相關(guān)蛋白2/端粒酶逆轉(zhuǎn)錄酶抗體規(guī)格 英文名稱  Anti-TERT

中文名稱  端粒酶相關(guān)蛋白2/端粒酶逆轉(zhuǎn)錄酶抗體規(guī)格 

別    名 Telomerase catalytic subunit; EST2; hEST2; TCS1; Telomerase associated protein 2; Telomere Reverse Transcriptase; TERT; TP2; TRT; Telomerase reverse transcriptase; Telomerase Catalytic Subunit; Telomerase-associated protein 2; TERT_HUMAN.

產(chǎn)品屬性：

濃    度  1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來源  Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human

產(chǎn)品類型   一抗  

研究領(lǐng)域     細(xì)胞生物 發(fā)育生物學(xué) 干細(xì)胞 細(xì)胞表面分子 細(xì)胞生物標(biāo)志物 表觀遺傳學(xué)

蛋白分子量  predicted molecular weight: 126kDa 

性    狀   Lyophilized or Liquid

免 疫 原  KLH conjugated synthetic peptide derived from hu TERT/EST2/Telomerase reverse transcriptase

亞    型  IgG

純化方法   affinity purified by Protein A

儲 存 液   Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

端粒酶相關(guān)蛋白2/端粒酶逆轉(zhuǎn)錄酶抗體規(guī)格 產(chǎn)品應(yīng)用   WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 Telomerase is a ribonucleoprotein polymerase that maintains telomere ends by addition of the telomere repeat TTAGGG. The enzyme consists of a protein component with reverse transcriptase activity, encoded by this gene, and an RNA component which serves as a template for the telomere repeat. Telomerase expression plays a role in cellular senescence, as it is normally repressed in postnatal somatic cells resulting in progressive shortening of telomeres. Deregulation of telomerase expression in somatic cells may be involved in oncogenesis. Studies in mouse suggest that telomerase also participates in chromosomal repair, since de novo synthesis of telomere repeats may occur at double-stranded breaks. Alternatively spliced variants encoding different isoforms of telomerase reverse transcriptase have been identified; the full-length sequence of some variants has not been determined. Alternative splicing at this locus is thought to be one mechanism of regulation of telomerase activity. [provided by RefSeq, Jul 2008].

Function : Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis.

Subunit : Homodimer; dimerization is required to produce a functional complex. Oligomer; can form oligomers in the absence of the telomerase RNA template component (TERC). Catalytic subunit of the telomerase holoenzyme complex composed minimally of TERT and TERC. The telomerase complex is composed of TERT, DKC1, WDR79/TCAB1, NOP10, NHP2, GAR1, TEP1, EST1A, POT1 and a telomerase RNA template component (TERC). The molecular chaperone HSP90/P23 complex is required for correct assembly and stabilization of the active telomerase. Interacts directly with HSP90A and PTGES3. Interacts with HSPA1A; the interaction occurs in the absence of TERC and dissociates once the complex has formed. Interacts with RAN; the interaction promotes nuclear export of TERT. Interacts with XPO1. Interacts with PTPN11; the interaction retains TERT in the nucleus. Interacts with NCL (via RRM1 and C-terminal RRM4/Arg/Gly-rich domains); the interaction is important for nucleolar localization of TERT. Interacts with SMARCA4 (via the bromodomain); the interaction regulates Wnt-mediated signaling. Interacts with MCRS1 (isoform MCRS2); the interaction inhibits in vitro telomerase activity. Interacts with PIF1; the interaction has no effect on the elongation activity of TERT. Interacts with PML; the interaction recruits TERT to PML bodies and inhibits telomerase activity.

Subcellular Location : Nucleus, nucleolus. Nucleus, nucleoplasm. Nucleus. Chromosome, telomere. Cytoplasm. Nucleus, PML body. Note=Shuttling between nuclear and cytoplasm depends on cell cycle, phosphorylation states, transformation and DNA damage. Diffuse localization in the nucleoplasm. Enriched in nucleoli of certain cell types. Translocated to the cytoplasm via nuclear pores in a CRM1/RAN-dependent manner involving oxidative stress-mediated phosphorylation at Tyr-707. Dephosphorylation at this site by SHP2 retains TERT in the nucleus. Translocated to the nucleus by phosphorylation by AKT.

Tissue Specificity : Expressed at a high level in thymocyte subpopulations, at an intermediate level in tonsil T-lymphocytes, and at a low to undetectable level in peripheral blood T-lymphocytes.

Post-translational modifications : Ubiquitinated, leading to proteasomal degradation.

Phosphorylation at Tyr-707 under oxidative stress leads to translocation of TERT to the cytoplasm and reduces its antiapoptotic activity. Dephosphorylated by SHP2/PTPN11 leading to nuclear retention. Phosphorylation by the AKT pathway promotes nuclear location.

DISEASE : Note=Activation of telomerase has been implicated in cell immortalization and cancer cell pathogenesis.

Defects in TERT are associated with susceptibilty to aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis.

Note=Genetic variations in TERT are associated with coronary artery disease (CAD).

Defects in TERT are the cause of dyskeratosis congenital autosomal dominant type 2 (DKCA2) [MIM:613989]. A rare multisystem disorder caused by defective telomere maintenance. It is characterized by progressive bone marrow failure, and the clinical triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Common but variable features include premature graying, aplastic anemia, low platelets, osteoporosis, pulmonary fibrosis, and liver fibrosis among others. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy.

Defects in TERT are the cause of dyskeratosis congenital autosomal recessive type 4 (DKCB4) [MIM:613989]. A rare multisystem disorder caused by defective telomere maintenance. It is characterized by progressive bone marrow failure, and the clinical triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Common but variable features include premature graying, aplastic anemia, low platelets, osteoporosis, pulmonary fibrosis, and liver fibrosis among others. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy.

Defects in TERT are a cause of susceptibility to pulmonary fibrosis idiopathic (IPF) [MIM:178500]. Pulmonary fibrosis is a lung disease characterized by shortness of breath, radiographically evident diffuse pulmonary infiltrates, and varying degrees of inflammation and fibrosis on biopsy. It results in acute lung injury with subsequent scarring and endstage lung disease.

Similarity : Belongs to the reverse transcriptase family. Telomerase subfamily.

Contains 1 reverse transcriptase domain.

Database links : UniProtKB/Swiss-Prot: O14746.1

實驗流程：

全、新、優(yōu)、品、好四大特點：

端粒酶相關(guān)蛋白2/端粒酶逆轉(zhuǎn)錄酶抗體規(guī)格 全：公司提供上萬種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標(biāo)準(zhǔn)品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細(xì)胞等，基本上各種科研所需產(chǎn)品在我司都能找到。

新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。

優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。

好：我公司具有優(yōu)質(zhì)的技術(shù)團(tuán)隊，產(chǎn)品一旦售出，實驗過程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時沒有任何的后顧之憂。

正在熱銷的相關(guān)產(chǎn)品：

KGF 人角蛋白生長因子Multi-class antibodies

Anti-Cystatin 3/CST3 胱抑素C/半胱氨酸蛋白酶抑制劑C抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh NF-H/Neurofilament H/Neurofilament 200 高分子量神經(jīng)絲蛋白抗體 規(guī)格 0.1ml

human ubiquitin D,UBD ELISA Kit 人泛素蛋白D 96T

TTX 英文名稱： 河素抗體 0.2ml

Cadherin 20 英文名稱： 鈣粘蛋白20抗體 0.1ml

Anti-Cystatin 3/CST3 胱抑素C/半胱氨酸蛋白酶抑制劑C抗體Multi-class antibodies規(guī)格： 0.1ml

PLAUR/uPAR ELISA Kit 大鼠尿激酶型纖溶酶原激活物受體Multi-class antibodies規(guī)格： 48T

Anti-Anthrax/FITC 熒光素標(biāo)記抗體(采用活疫苗制備)IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh FAM89B/MMTV-R 病毒受體同源蛋白抗體 規(guī)格 0.2ml

sE-selectin(Human soluble E-selectin) ELISA Kit 人可溶性E選擇素 96T

phospho-MAP4K4(Ser631) 英文名稱： 磷酸化原活化蛋白激酶MAP4K4抗體 0.1ml

ACVRL1 英文名稱： 激活素受體樣激酶1抗體 0.2ml

Anti-Anthrax/FITC 熒光素標(biāo)記抗體(采用活疫苗制備)IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-Wnt2B/FITC 熒光素標(biāo)記信號通路Wnt2B抗體IgGMulti-class antibodies規(guī)格： 0.2ml

CNGA2(Cyclic Nucleotide Gated Cation Alpha 2) 環(huán)核苷酸陽離子通道蛋白α2抗原Multi-class antibodies規(guī)格： 0.5mg

丙氨酰tRNA合成酶2抗體 Anti-AARS2 0.1ml

SARM1 英文名稱： SARM1蛋白抗體 0.2ml

EphB1+EphB2 英文名稱： 蛋白激酶受體B1+B2抗體 0.2ml

Rhesus antibody Rh Phospho-FoxO3a (Ser294) 磷酸化叉頭蛋白3A抗體 規(guī)格 0.1ml

CNGA2(Cyclic Nucleotide Gated Cation Alpha 2) 環(huán)核苷酸陽離子通道蛋白α2抗原Multi-class antibodies規(guī)格： 0.5mg

大鼠磷酸化腺苷酸活化蛋白激酶(pAMPK)ELISA試劑盒 ，英文名： pAMPK ELISA Kit

人結(jié)締組織生長因子(CTGF)ELISA檢測試劑盒Humanconnectivetissuegrowthfactor,CTGFELISAKit 96T/48T

蜥蜴25羥基膽固醇(25-OHC)免疫試劑盒 Lizard 25-hydroxycholesterol,25-OHC ELISA kit

CLIAKitforOXR(HumanOrexieceptor)ELISAKit人食欲素受體規(guī)格：48T/96T

隨機(jī)引物DNA探針聚合酶標(biāo)記試劑盒10次

ELISAKitIL1Ra人白介素1受體拮抗劑規(guī)格：48T/96T

大鼠別孕烯醇酮/3α,5α-四氫孕酮(AP/3α,5α-THP)ELISA試劑盒 ，英文名： AP/3α,5α-THP ELISA Kit

Mouse alpha glucosidase (alpha -glucosidase) ELISA Kit 小鼠α葡萄糖苷酶(α-glucosidase)ELISA試劑盒

ELISA 小鼠凋亡相關(guān)因子(mouse Fas) 48T/96T 進(jìn)口分裝

CLIAKitfom-1(HumanKidneyinjurymolecule1)ELISAKit人腎損傷分子1規(guī)格：48T/96T

通用型蛋白免疫共沉淀(蛋白A樹脂)試劑盒10次

ELISAKitMHCⅢ/H-1Ⅲ大鼠主要組織相容性復(fù)合體Ⅲ類規(guī)格：48T/96T

端粒酶相關(guān)蛋白2/端粒酶逆轉(zhuǎn)錄酶抗體規(guī)格 大鼠蛋白激酶C epsilon(PKCε)ELISA試劑盒 ，英文名： PKCε ELISA Kit

Porcine von Willebrand factor / ristocetin cofactor (VWF) ELISA Kit 豬性因子/瑞斯托霉素輔因子(VWF)ELISA試劑盒

病毒H9亞型核酸檢測試劑盒(熒光PCR法) 48T

CLIAKitforLp-PL-A2(Humanlipoprotein-associatedphospholipaseA2)ELISAKit人脂蛋脂酶A2規(guī)格：48T/96T

通用細(xì)胞/組織載玻片制備試劑盒20次

ELISAKitPRL雞催乳素規(guī)格：48T/96T

技術(shù)外包服務(wù):

★端粒酶相關(guān)蛋白2/端粒酶逆轉(zhuǎn)錄酶抗體規(guī)格 分子生物學(xué)：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學(xué)：基因合成、引物合成、基因測序、載體構(gòu)建等

★蛋白工程：原核、哺乳動物蛋白表達(dá)系統(tǒng)等

★病毒包裝：腺病毒、慢病毒等

★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★細(xì)胞工程：細(xì)胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復(fù)、克隆形成)、細(xì)胞培養(yǎng)、細(xì)胞膜制備、穩(wěn)定細(xì)胞株構(gòu)建、細(xì)胞RNAi技術(shù)等等。